A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. [electronic resource]
Producer: 20120508Description: 613-7 p. digitalISSN:- 1476-4687
- AMP-Activated Protein Kinases
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Benzimidazoles -- pharmacology
- Biomarkers, Tumor -- genetics
- Clinical Trials, Phase II as Topic
- Disease Models, Animal
- Docetaxel
- Drug Evaluation, Preclinical
- Fluorodeoxyglucose F18
- Genes, p53 -- genetics
- Humans
- Lung Neoplasms -- drug therapy
- MAP Kinase Signaling System -- drug effects
- Mice
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Mutation -- genetics
- Pharmacogenetics -- methods
- Positron-Emission Tomography
- Protein Serine-Threonine Kinases -- deficiency
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins p21(ras) -- genetics
- Randomized Controlled Trials as Topic
- Reproducibility of Results
- Taxoids -- therapeutic use
- Tomography, X-Ray Computed
- Treatment Outcome
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.